The role of αv integrins during angiogenesis: Insights into potential mechanisms of action and clinical development

Journal of Clinical Investigation

Volumn 103, Issue 9, 1999, Pages 1227-1230

  Eliceiri, Brian P ^a   Cheresh, David A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; CD51 ANTIGEN; LEUKOCYTE ANTIGEN;

ANGIOGENESIS; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVIEW; TUMOR BLOOD FLOW; ADULT; ANIMAL; CELL SURVIVAL; CYTOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADULT; ANIMALS; ANTIGENS, CD; CELL SURVIVAL; ENDOTHELIUM, VASCULAR; HUMANS; INTEGRIN ALPHAV; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0033121275     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6869     Document Type: Review

References (18)

1. Aplin, A.E., Howe, A., Alahari, S.K., and Juliano, R.L. 1998. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol. Rev. 50:197-263.
2. Felding-Habermann, B., Mueller, B.M., Romerdahl, C.A., and Cheresh, D.A. 1992. Involvement of integrin αv gene expression in human melanoma tumorigenicity. J. Clin. Invest. 89:2018-2022.
3. Enenstein, J., and Kramer, R.H. 1994. Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. J. Invest. Dermatol. 103:381-386.
4. Brooks, P.C., Clark, R.A., and Cheresh, D.A. 1994. Requirement of vascular integrin αβ3 for angiogenesis. Science. 264:569-571.
5. Brooks, P.C., et al. 1994. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1157-1164.
6. Storgard, CM., et al. 1999. Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist. J. Clin. Invest. 103:47-54.
7. Sipkins, D.A., et al. 1998. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nat. Med. 4:623-626.
8. Drake, C.J., Cheresh, D.A., and Little, C.D. 1995. An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell Sci. 108:2655-2661.
9. Brooks, P.C., et al. 1995. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96:1815-1822.
10. Friedlander, M., et al. 1995. Definition of two angiogenic pathways by distinct av integrins. Science. 270:1500-1502.
11. Hammes, H.P., Brownlee, M. Jonczyk, A., Sutter, A., and Preissner, K.T. 1996. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. 2:529-533.
12. Brooks, P.C., et al. 1996. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell. 85:683-693.
13. Brooks, P.C., Silletti, S., von Schalscha, T.L., Friedlander, M., and Cheresh, D.A. 1998. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 92:391-400.
14. Bader, B.L., Rayburn, H., Crowley, D., and Hynes, R.O. 1998. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell. 95:507-519.
15. Hodivala-Dilke, K.M., et al. 1999. β3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103:229-238.
16. Yang, J.T., Rayburn, H., and Hynes, R.O. 1993. Embryonic mesodermal defects in α5 integrin-deficient mice. Development. 119:1093-1105.
17. Eliceiri, B.P., Klemke, R., Stromblad, S., and Cheresh, D.A. 1998. Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J. Cell Biol. 140:1255-1263.
18. Stromblad, S., Becker, J.C., Yebra, M., Brooks, P.C., and Cheresh, D.A. 1996. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis. J. Clin. Invest. 98:426-433.